Loren Data's FBO Daily™

Home Today's FBO Search Archives Numbered Notes CBD Archives Subscribe

B -- Assessment of microRNA

Notice Date
Notice Type
Combined Synopsis/Solicitation
541380 — Testing Laboratories
Contracting Office
Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
ZIP Code
Solicitation Number
Archive Date
Point of Contact
Howard Nesmith, Phone: 870-543-7459
E-Mail Address
Small Business Set-Aside
This is a combined synopsis/solicitation for commercial items prepared in accordance with the Federal Acquisition Regulation (FAR) format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. The government intends to issue a Purchase Order in accordance with FAR PART 13.106 for the requirement herein under Simplified Acquisition Procedures. The solicitation number is FDA_13-233-1118687. This solicitation is issued as a Request for Quote (RFQ). The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2005-66, April 1, 2013. The associated North American Industry Classification System (NAICS) Code is- 541380 - Testing Laboratories; Size standards $12 million. This combined synopsis/solicitation is available for "Full and Open" competition. Respondents are responsible for delivery in person, by e-mail, fax, mail or other delivery method their complete proposal and any additional documents before 1:00 pm (Central Standard Time - Local Prevailing Time in Jefferson, Arkansas) on June 17, 2013 to howard.nesmith@fda.hhs.gov, Fax (870) 543-7990, or mail to the U. S. Food and Drug Administration, OO/OFBA/OAGS, Attention of Howard Nesmith, 3900 NCTR Road, Jefferson, AR 72079-9502. PLEASE NOTE - The above contact information is for the Contracting Office and not necessarily the delivery address. The delivery address is indicated in the FOB Destination section below. For information regarding this solicitation, please contact Howard Nesmith by e-Mail at howard.nesmith@fda.hhs.gov. The U.S. Food and Drug Administration's (FDA) National Center for Toxicological Research (NCTR), Jefferson, AR requires services for the assessment of micro RNA (miRNA) expression changes in human samples using Next-Generation sequencing technology (NextGen). Statement of Work (SOW) The U.S. Food and Drug Administration's (FDA) National Center for Toxicological Research (NCTR), Jefferson, AR requires services for the assessment of micro RNA (miRNA) expression changes in human samples using Next-Generation sequencing technology (NextGen). Next-Gen is required in order to provide full coverage of all the miRNA expressed in these samples. The Illumina sequencing technology is required since other projects at NCTR have used this sequencing chemistry/technology and NCTR needs to be able to make one to one comparisons between the data without introducing bias that may occur with the use of different technologies. A total of 144 samples shall be analyzed so that NCTR can compare the effect of tobacco smoke on the cellular expression of the miRNA. The Government will provide 144 samples (a minimum of 1 ug of total RNA (including miRNA)) within six (6) months of award and the Contractor shall, within three (3) months of receipt of the samples: Independently assess the quantity and quality of the RNA to ensure that it is acceptable for sequencing. Technical Specifications: • Prepare DNA libraries from the RNA that can be run on the Next-Gen platform • Sequence the libraries using Illumina sequencing technology at 50 bases minimum per read and a minimum of 3 - 5 million reads per sample • Align the read data to the current reference human genome with transcript identifications assigned from miRBASE • Analyze data and provide analysis and outputs on portable hard drive(s) of sufficient capacity to hold all the data which shall include, at a minimum, the following: - Raw data file for each sample. Files shall be filtered to remove sequencing-specific adducts from the 3' end of each read - A table of the flow cell statistics outlining the quality and yield of the flow cell(s) where samples were clustered and sequenced - QC files regarding any presence of artifact/duplicate sequences, along with base distributions and qualities - Alignment of filtered reads to the human genome - Alignment file containing best alignments of each read to genome - De-multiplexing of Illumina barcodes, if applicable - Provision of a tab-delimited file containing normalized counts of each miRNA with human miRBase (Sanger) accession for each sample Item #1 Services for the assessment of micro RNA (miRNA) expression changes in human samples using Next-Generation sequencing technology (NextGen). Quantity: 144 Unit Price: ____________________ Extended Price: ________________ GSA Contract Number (if applicable): ________________________ Item #2 External Hard Drive up to 2 TB for Data Files Delivery Including domestic shipping Quantity: 1 Unit Price: ____________________ Extended Price: ________________ FOB Destination - U.S. Food and Drug Administration, National Center for Toxicological Research, 3900 NCTR Rd., Jefferson, AR 72079. Contract Type - Commercial Item - Firm fixed price. An official authorized to bind the Offeror must sign the terms and conditions of the offer. Offerors that fail to furnish required representations and certifications, or reject the terms and conditions of the solicitation, may be excluded from consideration. Contract clauses- The clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. (Feb 2012) The following addenda have been attached to the clause: The supplies and/or services delivered hereunder shall be inspected and accepted at destination by the contracting officer's representative (COR) specified at award. If the supplies or services are acceptable, the COR shall promptly forward a report of inspection and acceptance to the paying office. If the supplies or services are not acceptable, the COR shall document the nonconforming items/services and immediately notify the contracting officer. The following additional provisions and/or clauses apply and incorporated by reference and apply to this acquisition. Clauses and provisions can be obtained at http://www.acquisition.gov/far/ FAR Clause 52.204-4 Printed or Copied Double-Sided on Recycled Paper. (MAY 2011) FAR Clause 52.204-7 Central Contractor Registration. (DEC 2012) The following HHSAR clauses apply and can be obtained at the following website: http://farsite.hill.af.mil/VFHHSAR1.htm 352.202-1 Definitions JAN 2006 352.203-70 Anti-Lobbying JAN 2006 352.222-70 Contractor Cooperation in Equal Employment Opportunity Investigations OCT 2009 352.223-70 Safety and Health JAN 2006 352.231-71 Pricing of Adjustments JAN 2001 352.242-71 Tobacco-Free Facilities JAN 2006 The Contracting Officer is the only person with authority to act as agent of the Government under this contract. Only the Contracting Officer has authority to: (1) Direct or negotiate any changes in the statement of work; (2) Modify or extend the period of performance; (3) change the delivery schedule; (4) Authorize reimbursement to the Contractor any costs incurred during the performance of this contract; or (5) Otherwise change any terms and conditions of this contract. The Contracting Officer for this order is: To be completed at time of award: Phone: (870) 543-XXXX Email: xxxx The COR is responsible for: (1) Monitoring the Contractor's technical progress, including the surveillance and assessment of performance and recommending to the Contracting Officer changes in requirements; (2) Interpreting the statement of work and any other technical performance requirements; (3) Performing technical evaluation as required; (4) Performing technical inspections and acceptances required by this contract; and (5) Assisting in the resolution of technical problems encountered during performance. The COR for this order is: to be completed at time of award. The clause at FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items (Nov 2012), applies to this acquisition. The following additional FAR clauses cited in this clause are applicable: 52.204-10, 52.209-6, 52.219-28, 52.222-3, 52.222-19, 52.222-21, 52.222-26, 52.222-36, 52.222-40, 52.223-18, 52.225-13, and 52.232-33. Solicitation provisions The provision at FAR 52.212-1 Instructions to Offerors - Commercial Items applies to this solicitation. Addendum Paragraph (c) Period for acceptance of offers. The offeror shall state on its quote that the quoted prices in its offer are firm until September 30, 2012. The provision at FAR 52.212-2 Evaluation-Commercial Items is applicable to this solicitation. The specific evaluation criteria to be included in paragraph (1) of that provision are as follows: The government will award the purchase order to the responsible offeror whose offer conforming to the solicitation will be the most advantageous to the Government on a best value (tradeoff) evaluation basis, price and other factors considered. The following factors shall be used to evaluate offers: (i) Technical acceptability of the services offered to meet the Government's requirement. (ii) Past Performance. (iii) Price. Non-price factors are more important than price in determining the best value. Technical acceptability will be determined by review of the technical approach proposed to meet the requirements of the SOW. Past Performance will be determined by review of recent (within the past 3 years) and relevant services for the assessment of micro RNA (miRNA) expression changes in human samples using Next-Generation sequencing technology (NextGen). The Government reserves the right to look to other sources of information (e.g., the Past Performance Information Retrieval System (PPIRS), etc.) to support past performance evaluations. The government is not responsible for locating or securing any information, which is not identified in the proposal. To ensure information is available, vendors must furnish as part of their proposal all descriptive material necessary for the government to determine whether the service meets the technical requirements. Quotes shall include technical specifications, descriptive material, literature, brochures and other information corresponding to each minimum required item, which demonstrates the capabilities of the offeror. The Provision at FAR 52.212-3, Offerors Representations and Certifications-Commercial Items, applies to this acquisition. An offeror shall complete only paragraph (b) of the provision if the offeror has completed the annual representations and certification electronically via http://www.acquisition.gov/far (Nov 2012) An offeror should complete only paragraph (b) of this provision if the offeror has completed the annual representations and certifications electronically at https://www.sam.gov. The Defense Priorities and Allocations System (DPAS) and assigned rating are not applicable to this solicitation notice. It is the offeror's responsibility to monitor the internet site for the release of an amendment to the combined synopsis/solicitation (if any).
Web Link
FBO.gov Permalink
Place of Performance
Address: U.S. Food and Drug Administration, National Center for Toxicological Research, 3900 NCTR Rd., Jefferson, Arkansas, 72079, United States
Zip Code: 72079
SN03080216-W 20130607/130606000455-4a7350c816fe2c212ffe4d94d6bcde06 (fbodaily.com)
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  © 1994-2016, Loren Data Corp.